News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

InViragen and University of Texas Medical School Receive Funding for Development of a Novel Recombinant Chikungunya Virus Vaccine



8/16/2011 8:53:51 AM

FORT COLLINS, Colo.--(BUSINESS WIRE)--Inviragen, Inc. today announced that the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health, has awarded a four-year grant of over $3 million for the characterization and development of a novel recombinant chikungunya virus (CHIKV) vaccine. The University of Texas Medical Branch (UTMB) in Galveston, which is collaborating with Inviragen on the development of a CHIKV vaccine, is the recipient of the grant, with over $1.5 million directly funding product development activities at Inviragen.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES